O	0	11	Therapeutic	Therapeutic	JJ	B-NP
O	12	21	targeting	targeting	NN	I-NP
O	22	24	of	of	IN	B-PP
O	25	28	the	the	DT	B-NP
O	29	37	survivin	survivin	NN	I-NP
O	38	45	pathway	pathway	NN	I-NP
O	46	48	in	in	IN	B-PP
B-Cancer	49	55	cancer	cancer	NN	B-NP
O	55	56	:	:	:	O
O	57	67	initiation	initiation	NN	B-NP
O	68	70	of	of	IN	B-PP
B-Cellular_component	71	84	mitochondrial	mitochondrial	JJ	B-NP
O	85	94	apoptosis	apoptosis	NN	I-NP
O	95	98	and	and	CC	I-NP
O	99	110	suppression	suppression	NN	I-NP
O	111	113	of	of	IN	B-PP
B-Cancer	114	119	tumor	tumor	NN	B-NP
O	119	120	-	-	HYPH	O
O	120	130	associated	associate	VBN	B-NP
O	131	143	angiogenesis	angiogenesis	NN	I-NP
O	143	144	.	.	.	O

O	145	152	PURPOSE	PURPOSE	NN	B-NP
O	152	153	:	:	:	O
O	154	163	Molecular	Molecular	JJ	B-NP
O	164	175	antagonists	antagonist	NNS	I-NP
O	176	178	of	of	IN	B-PP
O	179	182	the	the	DT	B-NP
O	183	192	inhibitor	inhibitor	NN	I-NP
O	193	195	of	of	IN	B-PP
O	196	205	apoptosis	apoptosis	NN	B-NP
O	206	213	protein	protein	NN	I-NP
O	214	222	survivin	survivin	NN	I-NP
O	223	227	have	have	VBP	B-VP
O	228	233	shown	show	VBN	I-VP
O	234	241	promise	promise	NN	B-NP
O	242	244	as	as	IN	B-PP
O	245	250	novel	novel	JJ	B-NP
B-Cancer	251	261	anticancer	anticancer	JJ	I-NP
O	262	272	strategies	strategy	NNS	I-NP
O	273	276	for	for	IN	B-PP
O	277	287	triggering	trigger	VBG	B-VP
B-Cell	288	293	tumor	tumor	NN	B-NP
I-Cell	294	298	cell	cell	NN	I-NP
O	299	308	apoptosis	apoptosis	NN	I-NP
O	308	309	,	,	,	O
O	310	323	dysregulating	dysregulate	VBG	B-VP
O	324	331	mitotic	mitotic	JJ	B-NP
O	332	343	progression	progression	NN	I-NP
O	343	344	,	,	,	O
O	345	348	and	and	CC	O
O	349	359	inhibiting	inhibit	VBG	B-VP
B-Cancer	360	365	tumor	tumor	NN	B-NP
O	366	372	growth	growth	NN	I-NP
O	373	375	in	in	IN	B-PP
O	376	387	preclinical	preclinical	JJ	B-NP
O	388	394	models	model	NNS	I-NP
O	394	395	.	.	.	O

O	396	403	However	However	RB	B-ADVP
O	403	404	,	,	,	O
O	405	408	how	how	WRB	B-ADVP
O	409	417	survivin	survivin	NN	B-NP
O	418	425	couples	couple	NNS	I-NP
O	426	428	to	to	TO	B-PP
O	429	432	the	the	DT	B-NP
B-Cell	433	437	cell	cell	NN	I-NP
O	438	443	death	death	NN	I-NP
O	444	453	machinery	machinery	NN	I-NP
O	454	457	has	have	VBZ	B-VP
O	458	466	remained	remain	VBN	I-VP
O	467	474	elusive	elusive	JJ	B-ADJP
O	474	475	,	,	,	O
O	476	479	and	and	CC	O
O	480	483	the	the	DT	B-NP
O	484	492	relevant	relevant	JJ	I-NP
B-Cell	493	501	cellular	cellular	JJ	I-NP
O	502	509	targets	target	NNS	I-NP
O	510	512	of	of	IN	B-PP
O	513	521	survivin	survivin	NN	B-NP
O	522	533	antagonists	antagonist	NNS	I-NP
O	534	538	have	have	VBP	B-VP
O	539	542	not	not	RB	I-VP
O	543	547	been	be	VBN	I-VP
O	548	558	completely	completely	RB	B-ADJP
O	559	569	elucidated	elucidate	VBN	I-ADJP
O	569	570	.	.	.	O

O	571	583	Experimental	Experimental	NNP	B-NP
O	584	590	Design	Design	NNP	I-NP
O	590	591	:	:	:	O
O	592	597	Human	Human	JJ	B-NP
B-Cell	598	607	umbilical	umbilical	JJ	I-NP
I-Cell	608	612	vein	vein	NN	I-NP
O	613	616	and	and	CC	O
B-Cell	617	623	dermal	dermal	JJ	B-NP
I-Cell	624	637	microvascular	microvascular	JJ	I-NP
I-Cell	638	649	endothelial	endothelial	JJ	I-NP
I-Cell	650	655	cells	cell	NNS	I-NP
O	656	660	were	be	VBD	B-VP
O	661	669	infected	infect	VBN	I-VP
O	670	674	with	with	IN	B-PP
O	675	686	replication	replication	NN	B-NP
O	686	687	-	-	HYPH	B-NP
O	687	696	deficient	deficient	JJ	I-NP
O	697	709	adenoviruses	adenovirus	NNS	I-NP
O	710	718	encoding	encode	VBG	B-VP
O	719	727	survivin	survivin	NN	B-NP
O	728	729	(	(	(	O
O	729	732	pAd	pAd	NN	B-NP
O	732	733	-	-	HYPH	B-NP
O	733	741	Survivin	Survivin	NN	I-NP
O	741	742	)	)	)	O
O	742	743	,	,	,	O
O	744	749	green	green	JJ	B-NP
O	750	761	fluorescent	fluorescent	JJ	I-NP
O	762	769	protein	protein	NN	I-NP
O	770	771	(	(	(	O
O	771	774	pAd	pAd	NN	B-NP
O	774	775	-	-	HYPH	B-NP
O	775	778	GFP	GFP	NN	I-NP
O	778	779	)	)	)	O
O	779	780	,	,	,	O
O	781	783	or	or	CC	O
O	784	785	a	a	DT	B-NP
O	786	801	phosphorylation	phosphorylation	NN	I-NP
O	801	802	-	-	HYPH	B-NP
O	802	811	defective	defective	JJ	I-NP
O	812	820	survivin	survivin	NN	I-NP
O	821	824	Thr	Thr	NN	I-NP
O	824	825	(	(	(	O
O	825	827	34	34	CD	B-NP
O	827	828	)	)	)	O
O	828	829	-	-	SYM	O
O	829	830	-	-	HYPH	O
O	830	831	>	>	SYM	O
O	831	834	Ala	Ala	NN	B-NP
O	835	836	(	(	(	O
O	836	839	pAd	pAd	NN	B-NP
O	839	840	-	-	HYPH	B-NP
O	840	844	T34A	T34A	NN	I-NP
O	844	845	)	)	)	I-NP
O	846	854	dominant	dominant	JJ	I-NP
O	855	863	negative	negative	JJ	I-NP
O	864	870	mutant	mutant	NN	I-NP
O	870	871	.	.	.	O

O	872	875	The	The	DT	B-NP
O	876	882	effect	effect	NN	I-NP
O	883	885	of	of	IN	B-PP
O	886	890	wild	wild	JJ	B-NP
O	890	891	-	-	HYPH	I-NP
O	891	895	type	type	NN	I-NP
O	896	898	or	or	CC	I-NP
O	899	905	mutant	mutant	JJ	I-NP
O	906	914	survivin	survivin	NN	I-NP
O	915	918	was	be	VBD	B-VP
O	919	931	investigated	investigate	VBN	I-VP
O	932	934	on	on	IN	B-PP
B-Multi-tissue_structure	935	944	capillary	capillary	JJ	B-NP
I-Multi-tissue_structure	945	952	network	network	NN	I-NP
O	953	962	stability	stability	NN	I-NP
O	962	963	,	,	,	O
B-Cell	964	975	endothelial	endothelial	JJ	B-NP
I-Cell	976	980	cell	cell	NN	I-NP
O	981	990	viability	viability	NN	I-NP
O	990	991	,	,	,	O
O	992	995	and	and	CC	O
O	996	1003	caspase	caspase	NN	B-NP
O	1004	1014	activation	activation	NN	I-NP
O	1015	1017	in	in	FW	B-ADVP
O	1018	1023	vitro	vitro	FW	I-ADVP
O	1024	1027	and	and	CC	O
O	1028	1030	on	on	IN	B-PP
O	1031	1039	kinetics	kinetic	NNS	B-NP
O	1040	1042	of	of	IN	B-PP
B-Cancer	1043	1048	tumor	tumor	NN	B-NP
O	1049	1055	growth	growth	NN	I-NP
O	1056	1059	and	and	CC	O
O	1060	1071	development	development	NN	B-NP
O	1072	1074	of	of	IN	B-PP
O	1075	1087	angiogenesis	angiogenesis	NN	B-NP
O	1088	1090	in	in	IN	B-PP
O	1091	1092	a	a	DT	B-NP
B-Cancer	1093	1099	breast	breast	NN	I-NP
I-Cancer	1100	1106	cancer	cancer	NN	I-NP
I-Cancer	1107	1116	xenograft	xenograft	NN	I-NP
O	1117	1122	model	model	NN	I-NP
O	1123	1125	in	in	FW	B-ADVP
O	1126	1130	vivo	vivo	FW	I-ADVP
O	1130	1131	.	.	.	O

O	1132	1135	The	The	DT	B-NP
B-Cell	1136	1140	cell	cell	NN	I-NP
O	1141	1146	death	death	NN	I-NP
O	1147	1154	pathway	pathway	NN	I-NP
O	1155	1164	initiated	initiate	VBN	B-VP
O	1165	1167	by	by	IN	B-PP
O	1168	1176	survivin	survivin	NN	B-NP
O	1177	1186	targeting	targeting	NN	I-NP
O	1187	1190	was	be	VBD	B-VP
O	1191	1197	mapped	map	VBN	I-VP
O	1198	1202	with	with	IN	B-PP
O	1203	1210	respect	respect	NN	B-NP
O	1211	1213	to	to	TO	B-PP
O	1214	1224	cytochrome	cytochrome	NN	B-NP
O	1225	1226	c	c	NN	I-NP
O	1227	1234	release	release	NN	I-NP
O	1234	1235	,	,	,	O
O	1236	1243	changes	change	NNS	B-NP
O	1244	1246	in	in	IN	B-PP
B-Cellular_component	1247	1260	mitochondrial	mitochondrial	JJ	B-NP
I-Cellular_component	1261	1274	transmembrane	transmembrane	JJ	I-NP
O	1275	1284	potential	potential	NN	I-NP
O	1284	1285	,	,	,	O
O	1286	1289	and	and	CC	O
O	1290	1300	apoptosome	apoptosome	NN	B-NP
O	1301	1313	requirements	requirement	NNS	I-NP
O	1314	1319	using	use	VBG	B-VP
O	1320	1325	mouse	mouse	NN	B-NP
B-Cell	1326	1335	embryonic	embryonic	JJ	I-NP
I-Cell	1336	1347	fibroblasts	fibroblast	NNS	I-NP
O	1348	1357	deficient	deficient	JJ	B-ADJP
O	1358	1360	in	in	IN	B-PP
O	1361	1365	Apaf	Apaf	NNP	B-NP
O	1365	1366	-	-	HYPH	B-NP
O	1366	1367	1	1	CD	I-NP
O	1368	1370	or	or	CC	I-NP
O	1371	1378	caspase	caspase	NN	I-NP
O	1378	1379	-	-	:	O
O	1379	1380	9	9	CD	B-NP
O	1380	1381	.	.	.	O

O	1382	1389	RESULTS	RESULTS	NNS	B-NP
O	1389	1390	:	:	:	O
O	1391	1401	Adenoviral	Adenoviral	JJ	B-NP
O	1402	1414	transduction	transduction	NN	I-NP
O	1415	1417	of	of	IN	B-PP
B-Cell	1418	1429	endothelial	endothelial	JJ	B-NP
I-Cell	1430	1435	cells	cell	NNS	I-NP
O	1436	1440	with	with	IN	B-PP
O	1441	1444	pAd	pAd	NN	B-NP
O	1444	1445	-	-	HYPH	B-NP
O	1445	1453	Survivin	Survivin	NN	I-NP
O	1454	1463	inhibited	inhibit	VBD	B-VP
O	1464	1470	growth	growth	NN	B-NP
O	1471	1477	factor	factor	NN	I-NP
O	1478	1489	deprivation	deprivation	NN	I-NP
O	1489	1490	-	-	HYPH	B-NP
O	1491	1493	or	or	CC	I-NP
O	1494	1502	ceramide	ceramide	NN	I-NP
O	1502	1503	-	-	HYPH	O
O	1503	1510	induced	induce	VBN	B-NP
O	1511	1520	apoptosis	apoptosis	NN	I-NP
O	1520	1521	,	,	,	O
O	1522	1529	reduced	reduce	VBD	B-VP
O	1530	1537	caspase	caspase	NN	B-NP
O	1537	1538	-	-	HYPH	B-NP
O	1538	1539	3	3	CD	I-NP
O	1540	1543	and	and	CC	O
O	1544	1545	-	-	SYM	B-NP
O	1545	1546	7	7	CD	B-NP
O	1547	1557	generation	generation	NN	I-NP
O	1557	1558	,	,	,	O
O	1559	1562	and	and	CC	O
O	1563	1573	stabilized	stabilize	VBD	B-VP
O	1574	1579	three	three	CD	B-NP
O	1579	1580	-	-	HYPH	I-NP
O	1580	1591	dimensional	dimensional	JJ	I-NP
B-Multi-tissue_structure	1592	1601	capillary	capillary	JJ	I-NP
I-Multi-tissue_structure	1602	1610	networks	network	NNS	I-NP
O	1611	1613	in	in	FW	B-ADVP
O	1614	1619	vitro	vitro	FW	I-ADVP
O	1619	1620	.	.	.	O

O	1621	1631	Conversely	Conversely	RB	B-ADVP
O	1631	1632	,	,	,	O
O	1633	1643	expression	expression	NN	B-NP
O	1644	1646	of	of	IN	B-PP
O	1647	1650	pAd	pAd	NN	B-NP
O	1650	1651	-	-	HYPH	B-NP
O	1651	1655	T34A	T34A	NN	I-NP
O	1656	1662	caused	cause	VBD	B-VP
O	1663	1672	apoptosis	apoptosis	NN	B-NP
O	1673	1675	in	in	IN	B-PP
B-Cell	1676	1685	umbilical	umbilical	JJ	B-NP
I-Cell	1686	1690	vein	vein	NN	I-NP
O	1691	1694	and	and	CC	O
B-Cell	1695	1701	dermal	dermal	JJ	B-NP
I-Cell	1702	1715	microvascular	microvascular	JJ	I-NP
I-Cell	1716	1727	endothelial	endothelial	JJ	I-NP
I-Cell	1728	1733	cells	cell	NNS	I-NP
O	1734	1737	and	and	CC	O
O	1738	1746	resulted	result	VBD	B-VP
O	1747	1749	in	in	IN	B-PP
O	1750	1757	caspase	caspase	NN	B-NP
O	1757	1758	-	-	HYPH	B-NP
O	1758	1759	3	3	CD	I-NP
O	1760	1768	activity	activity	NN	I-NP
O	1768	1769	.	.	.	O

B-Cell	1770	1774	Cell	Cell	NN	B-NP
O	1775	1780	death	death	NN	I-NP
O	1781	1788	induced	induce	VBN	B-VP
O	1789	1791	by	by	IN	B-PP
O	1792	1800	survivin	survivin	NN	B-NP
O	1801	1810	targeting	targeting	NN	I-NP
O	1811	1820	exhibited	exhibit	VBD	B-VP
O	1821	1824	the	the	DT	B-NP
O	1825	1834	hallmarks	hallmark	NNS	I-NP
O	1835	1837	of	of	IN	B-PP
B-Cellular_component	1838	1851	mitochondrial	mitochondrial	JJ	B-NP
O	1851	1852	-	-	HYPH	I-NP
O	1852	1861	dependent	dependent	JJ	I-NP
O	1862	1871	apoptosis	apoptosis	NN	I-NP
O	1872	1876	with	with	IN	B-PP
O	1877	1884	release	release	NN	B-NP
O	1885	1887	of	of	IN	B-PP
O	1888	1898	cytochrome	cytochrome	NN	B-NP
O	1899	1900	c	c	NN	I-NP
O	1901	1904	and	and	CC	I-NP
O	1905	1909	loss	loss	NN	I-NP
O	1910	1912	of	of	IN	B-PP
B-Cellular_component	1913	1926	mitochondrial	mitochondrial	JJ	B-NP
I-Cellular_component	1927	1940	transmembrane	transmembrane	JJ	I-NP
O	1941	1950	potential	potential	NN	I-NP
O	1951	1954	and	and	CC	O
O	1955	1958	was	be	VBD	B-VP
O	1959	1969	suppressed	suppress	VBN	I-VP
O	1970	1972	in	in	IN	B-PP
O	1973	1977	Apaf	Apaf	NN	B-NP
O	1977	1978	-	-	HYPH	B-NP
O	1978	1979	1	1	CD	I-NP
O	1980	1982	or	or	CC	I-NP
O	1983	1990	caspase	caspase	NN	I-NP
O	1990	1991	-	-	HYPH	B-NP
O	1991	1992	9	9	CD	I-NP
O	1993	2001	knockout	knockout	NN	I-NP
O	2002	2007	mouse	mouse	NN	I-NP
B-Cell	2008	2017	embryonic	embryonic	JJ	I-NP
I-Cell	2018	2029	fibroblasts	fibroblast	NNS	I-NP
O	2029	2030	.	.	.	O

O	2031	2035	When	When	WRB	B-ADVP
O	2036	2044	injected	inject	VBN	B-VP
O	2045	2047	in	in	IN	B-PP
O	2048	2053	human	human	JJ	B-NP
B-Cancer	2054	2060	breast	breast	NN	I-NP
I-Cancer	2061	2067	cancer	cancer	NN	I-NP
I-Cancer	2068	2078	xenografts	xenograft	NNS	I-NP
O	2078	2079	,	,	,	O
O	2080	2083	pAd	pAd	NN	B-NP
O	2083	2084	-	-	HYPH	I-NP
O	2084	2088	T34A	T34A	NN	I-NP
O	2089	2098	inhibited	inhibit	VBD	B-VP
O	2099	2105	growth	growth	NN	B-NP
O	2106	2108	of	of	IN	B-PP
O	2109	2120	established	establish	VBN	B-NP
B-Cancer	2121	2127	tumors	tumor	NNS	I-NP
O	2128	2131	and	and	CC	O
O	2132	2141	triggered	trigger	VBD	B-VP
B-Cell	2142	2147	tumor	tumor	NN	B-NP
I-Cell	2148	2152	cell	cell	NN	I-NP
O	2153	2162	apoptosis	apoptosis	NN	I-NP
O	2163	2165	in	in	FW	B-ADVP
O	2166	2170	vivo	vivo	FW	I-ADVP
O	2170	2171	.	.	.	O

O	2172	2176	This	This	DT	B-NP
O	2177	2180	was	be	VBD	B-VP
O	2181	2191	associated	associate	VBN	I-VP
O	2192	2196	with	with	IN	B-PP
O	2197	2198	a	a	DT	B-NP
O	2199	2212	approximately	approximately	RB	I-NP
O	2213	2215	60	60	CD	I-NP
O	2215	2216	%	%	NN	I-NP
O	2217	2226	reduction	reduction	NN	I-NP
O	2227	2229	in	in	IN	B-PP
B-Cancer	2230	2235	tumor	tumor	NN	B-NP
O	2235	2236	-	-	HYPH	O
O	2236	2243	derived	derive	VBN	B-NP
B-Multi-tissue_structure	2244	2249	blood	blood	NN	I-NP
I-Multi-tissue_structure	2250	2257	vessels	vessel	NNS	I-NP
O	2258	2260	by	by	IN	B-PP
O	2261	2273	quantitative	quantitative	JJ	B-NP
O	2274	2285	morphometry	morphometry	NN	I-NP
O	2286	2288	of	of	IN	B-PP
O	2289	2293	CD31	CD31	NN	B-NP
O	2293	2294	-	-	HYPH	O
O	2294	2301	stained	stain	VBN	B-NP
B-Cancer	2302	2307	tumor	tumor	NN	I-NP
O	2308	2313	areas	area	NNS	I-NP
O	2313	2314	,	,	,	O
O	2315	2318	and	and	CC	O
O	2319	2329	appearance	appearance	NN	B-NP
O	2330	2332	of	of	IN	B-PP
B-Cell	2333	2344	endothelial	endothelial	JJ	B-NP
I-Cell	2345	2349	cell	cell	NN	I-NP
O	2350	2359	apoptosis	apoptosis	NN	I-NP
O	2360	2362	by	by	IN	B-PP
O	2363	2379	internucleosomal	internucleosomal	JJ	B-NP
O	2380	2383	DNA	DNA	NN	I-NP
O	2384	2397	fragmentation	fragmentation	NN	I-NP
O	2398	2400	in	in	FW	B-ADVP
O	2401	2405	vivo	vivo	FW	I-ADVP
O	2405	2406	.	.	.	O

O	2407	2418	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	2418	2419	:	:	:	O
O	2420	2428	Survivin	Survivin	NN	B-NP
O	2429	2438	functions	function	VBZ	B-VP
O	2439	2441	as	as	IN	B-PP
O	2442	2443	a	a	DT	B-NP
O	2444	2449	novel	novel	JJ	I-NP
O	2450	2458	upstream	upstream	JJ	I-NP
O	2459	2468	regulator	regulator	NN	I-NP
O	2469	2471	of	of	IN	B-PP
B-Cellular_component	2472	2485	mitochondrial	mitochondrial	JJ	B-NP
O	2485	2486	-	-	HYPH	I-NP
O	2486	2495	dependent	dependent	JJ	I-NP
O	2496	2505	apoptosis	apoptosis	NN	I-NP
O	2505	2506	,	,	,	O
O	2507	2510	and	and	CC	O
O	2511	2520	molecular	molecular	JJ	B-NP
O	2521	2530	targeting	targeting	NN	I-NP
O	2531	2533	of	of	IN	B-PP
O	2534	2538	this	this	DT	B-NP
O	2539	2546	pathway	pathway	NN	I-NP
O	2547	2554	results	result	VBZ	B-VP
O	2555	2557	in	in	IN	B-PP
B-Cancer	2558	2568	anticancer	anticancer	JJ	B-NP
O	2569	2577	activity	activity	NN	I-NP
O	2578	2581	via	via	IN	B-PP
O	2582	2583	a	a	DT	B-NP
O	2584	2588	dual	dual	JJ	I-NP
O	2589	2598	mechanism	mechanism	NN	I-NP
O	2599	2601	of	of	IN	B-PP
O	2602	2611	induction	induction	NN	B-NP
O	2612	2614	of	of	IN	B-PP
B-Cell	2615	2620	tumor	tumor	NN	B-NP
I-Cell	2621	2625	cell	cell	NN	I-NP
O	2626	2635	apoptosis	apoptosis	NN	I-NP
O	2636	2639	and	and	CC	O
O	2640	2651	suppression	suppression	NN	B-NP
O	2652	2654	of	of	IN	B-PP
O	2655	2667	angiogenesis	angiogenesis	NN	B-NP
O	2667	2668	.	.	.	O

